Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKYANASDAQ:BNGONASDAQ:HLTHNASDAQ:NAUT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKYAAkoya Biosciences$1.16+5.5%$1.32$1.01▼$4.42$57.86M1.34350,344 shs305,329 shsBNGOBionano Genomics$3.91+1.8%$3.67$2.68▼$72.60$12.13M2.3696,738 shs70,473 shsHLTHCue Health$0.04-29.8%$0.07$0.04▼$0.74$6.91M1.0913.38 million shs96.00 million shsNAUTNautilus Biotechnology$0.72+3.3%$0.84$0.66▼$3.09$91.21M1.41112,472 shs141,890 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKYAAkoya Biosciences+3.57%-7.20%-6.45%-49.34%-72.80%BNGOBionano Genomics+1.82%-1.01%-13.50%-27.59%-93.18%HLTHCue Health0.00%0.00%0.00%0.00%-66.33%NAUTNautilus Biotechnology+3.29%+5.52%-8.60%-54.81%-73.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKYAAkoya Biosciences1.9297 of 5 stars3.03.00.00.01.81.70.6BNGOBionano Genomics1.5435 of 5 stars3.12.00.00.02.70.00.6HLTHCue HealthN/AN/AN/AN/AN/AN/AN/AN/ANAUTNautilus Biotechnology3.0264 of 5 stars3.03.00.00.03.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKYAAkoya Biosciences 2.00Hold$3.21176.58% UpsideBNGOBionano Genomics 2.25Hold$44.671,042.37% UpsideHLTHCue Health 0.00N/AN/AN/ANAUTNautilus Biotechnology 2.00Hold$2.42234.26% UpsideCurrent Analyst Ratings BreakdownLatest NAUT, HLTH, AKYA, and BNGO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$3.50 ➝ $1.804/14/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.40 ➝ $1.654/9/2025BNGOBionano GenomicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/2/2025BNGOBionano GenomicsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$1.00 ➝ $4.003/25/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$3.50 ➝ $1.803/18/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$3.50 ➝ $3.503/5/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$2.402/28/2025NAUTNautilus BiotechnologyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.50(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKYAAkoya Biosciences$81.67M0.71N/AN/A$1.10 per share1.05BNGOBionano Genomics$30.78M0.39N/AN/A$125.85 per share0.03HLTHCue Health$70.94M0.10N/AN/A$1.62 per share0.03NAUTNautilus BiotechnologyN/AN/AN/AN/A$2.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKYAAkoya Biosciences-$63.32M-$1.13N/AN/AN/A-66.77%-162.99%-32.76%N/ABNGOBionano Genomics-$232.49M-$138.92N/A∞N/A-407.34%-154.45%-80.78%5/14/2025 (Estimated)HLTHCue Health-$373.46M-$2.44N/AN/AN/A-526.48%-67.82%-53.79%N/ANAUTNautilus Biotechnology-$63.67M-$0.54N/AN/AN/AN/A-28.85%-24.93%7/29/2025 (Estimated)Latest NAUT, HLTH, AKYA, and BNGO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BNGOBionano Genomics-$3.49N/AN/AN/A$6.25 millionN/A5/12/2025Q1 2025AKYAAkoya Biosciences-$0.29-$0.32-$0.03-$0.32$20.19 million$16.64 million4/29/2025Q1 2025NAUTNautilus Biotechnology-$0.14-$0.13+$0.01-$0.13N/AN/A3/17/2025Q4 2024AKYAAkoya Biosciences-$0.15-$0.17-$0.02-$0.17$21.34 million$21.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKYAAkoya BiosciencesN/AN/AN/AN/AN/ABNGOBionano GenomicsN/AN/AN/AN/AN/AHLTHCue HealthN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKYAAkoya Biosciences5.622.751.85BNGOBionano Genomics0.071.430.99HLTHCue HealthN/A2.542.22NAUTNautilus BiotechnologyN/A16.6516.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKYAAkoya Biosciences79.42%BNGOBionano Genomics11.35%HLTHCue Health45.49%NAUTNautilus Biotechnology50.71%Insider OwnershipCompanyInsider OwnershipAKYAAkoya Biosciences7.30%BNGOBionano Genomics1.60%HLTHCue Health12.50%NAUTNautilus Biotechnology40.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKYAAkoya Biosciences9049.88 million45.95 millionOptionableBNGOBionano Genomics3003.10 million1.92 millionOptionableHLTHCue Health726159.09 million139.21 millionOptionableNAUTNautilus Biotechnology130126.15 million74.71 millionOptionableNAUT, HLTH, AKYA, and BNGO HeadlinesRecent News About These CompaniesShort Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Grows By 29.3%May 4, 2025 | americanbankingnews.comNautilus Biotechnology (NASDAQ:NAUT) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPSMay 1, 2025 | marketbeat.comEarnings call transcript: Nautilus Biotechnology Q1 2025 surprises with EPS beatMay 1, 2025 | uk.investing.comNautilus Biotechnology Inc (NAUT) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions ...April 30, 2025 | finance.yahoo.comWhy Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 7.04%April 30, 2025 | aaii.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call TranscriptApril 30, 2025 | msn.comQ1 2025 Nautilus Biotechnology Inc Earnings CallApril 30, 2025 | uk.finance.yahoo.comNautilus Biotechnology targets late 2026 platform launch amid proteoform assay advancementsApril 29, 2025 | msn.comNautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comNautilus Biotechnology Reports First Quarter 2025 Financial ResultsApril 29, 2025 | manilatimes.netNautilus Biotechnology (NAUT) Projected to Post Earnings on TuesdayApril 24, 2025 | marketbeat.comShort Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Expands By 20.5%April 23, 2025 | marketbeat.comNautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025April 18, 2025 | seekingalpha.comWhy Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 10.19%April 9, 2025 | aaii.comWe're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn RateApril 1, 2025 | finance.yahoo.comInsider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Purchases 53,300 Shares of StockMarch 22, 2025 | insidertrades.comGlobal Research Antibodies Market Poised for Remarkable Growth, Projected to Reach USD 9.6 Billion by 2032 | FMIMarch 4, 2025 | fmiblog.comNautilus Biotechnology price target lowered to $2.50 from $4 at GuggenheimFebruary 28, 2025 | markets.businessinsider.comNautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comNautilus Biotechnology Inc (NAUT) Q4 2024 Earnings Call Highlights: Progress in Proteome ...February 28, 2025 | finance.yahoo.comNautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026February 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAUT, HLTH, AKYA, and BNGO Company DescriptionsAkoya Biosciences NASDAQ:AKYA$1.16 +0.06 (+5.45%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.16 +0.00 (+0.09%) As of 05:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.Bionano Genomics NASDAQ:BNGO$3.91 +0.07 (+1.82%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$3.96 +0.04 (+1.15%) As of 08:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.Cue Health NASDAQ:HLTHCue Health Inc. operates as a healthcare technology company. It provides the Cue Health platform that offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a range of health and wellness needs. It offers Cue Integrated Care platform comprising hardware, software, and diagnostic components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, including integration with electronic medical record system, pharmacies and last-mile delivery, clinician networks, and laboratories. The company also provides COVID-19 testing kits. The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.Nautilus Biotechnology NASDAQ:NAUT$0.72 +0.02 (+3.29%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.74 +0.02 (+2.49%) As of 05/12/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
